Highlights From the ASGCT 25th Annual Meeting
A Factor VIII Variant With Elimination of the N-glycosylation Site at 2118 Reduced Anti-FVIII Immune Responses in Gene Therapy Treated Hemophilia A Mice
Presented by: Carol H. Miao, MD, Seattle Children’s Research Institute, Seattle, Washington, United States
Carol H. Miao1,4, Meng-Ni Fan1, Shuaishuai Wang2, Junping Zhang3, Xiaohe Cai1, Ting-Yen Chao1, Lei Li2, Weidong Xiao3, Barbara A. Konkle4
1Seattle Children’s Research Institute, Seattle, WA
2Georgia State University, Atlanta, GA
3Indiana University, Indianapolis, IN
4University of Washington, Seattle, WA
RELATED CONTENT
Interactive Webinars
Long-term Outcomes: Durability and Safety
Presented by Prof. Margareth C. Ozelo, MD, PhD...
Obstacles and Opportunities
Presented by Frank W.G. Leebeek, MD, PhD...
Patient Support, Patient Counseling, and Monitoring
Presented by Lindsey A. George, MD...
Gene Therapy for FVIII
Presented by K. John Pasi, MB ChB, PhD, FRCP, FRCPath, FRCPC...
Update on Efficacy of Clinical Trials
Presented by Guy Young, MD...
Adeno-Associated Viral (AAV) Vector Gene Therapy: Application to Hemophilia
Presented by Barbara A. Konkle, MD...
Gene Therapy for Treatment of Hemophilia: An Introduction to Adeno-Associated Viral Vector Gene Transfer
Presented by Johnny Mahlangu, BSc, MBBCh, MMed, FCPath...
Gene Therapy for Treatment of Hemophilia: Common Concerns in Gene Therapy
Presented by Thierry VandenDriessche, PhD...
Gene Therapy for Treatment of Hemophilia: Other Strategies and Targets
Presented by Glenn F. Pierce, MD, PhD...
A History of Hemophilia Treatment: Non-replacement Therapy to Gene Therapy
Presented by Steven W. Pipe, MD...
Getting to Know Gene Therapy: Terminology and Concepts
Presented by David Lillicrap, MD...
A History of Hemophilia Treatment: Factor Replacement to Gene Therapy
Presented by Flora Peyvandi, MD, PhD...
Podcasts